JPWO2021113829A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021113829A5 JPWO2021113829A5 JP2022533152A JP2022533152A JPWO2021113829A5 JP WO2021113829 A5 JPWO2021113829 A5 JP WO2021113829A5 JP 2022533152 A JP2022533152 A JP 2022533152A JP 2022533152 A JP2022533152 A JP 2022533152A JP WO2021113829 A5 JPWO2021113829 A5 JP WO2021113829A5
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticle composition
- ferric chloride
- dextran
- ferrous chloride
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 82
- 239000002105 nanoparticle Substances 0.000 claims description 58
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 34
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 34
- 229960002089 ferrous chloride Drugs 0.000 claims description 32
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 32
- 229920002307 Dextran Polymers 0.000 claims description 26
- 239000002122 magnetic nanoparticle Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 14
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 12
- 125000003277 amino group Chemical group 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- 238000003384 imaging method Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 150000002338 glycosides Chemical class 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000004132 cross linking Methods 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 229930182470 glycoside Natural products 0.000 claims description 4
- UBUHAZKODAUXCP-UHFFFAOYSA-N iron(2+);oxygen(2-);hydrate Chemical class O.[O-2].[Fe+2] UBUHAZKODAUXCP-UHFFFAOYSA-N 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 239000010839 body fluid Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000002872 contrast media Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 150000004676 glycans Polymers 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- -1 antibody Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Description
他の実施形態
本発明をその詳細な説明と合わせて説明したが、前述の説明は、添付の特許請求の範囲によって定義される本発明の範囲を例示することを意図しており、限定することを意図していないことを理解されたい。他の態様、利点、および改変は、以下の特許請求の範囲の範囲内にある。
以下に、本願の当初の特許請求の範囲に記載された発明を付記する。
［１］ 塩化第二鉄、塩化第一鉄、またはそれらの組合せと、
１つ以上のアミン基で官能化されたデキストランコーティングと
を含む磁性ナノ粒子を含み、
前記１つ以上のアミン基の数が約５～約１０００の範囲である、ナノ粒子組成物。
［２］ 約５０重量（ｗｔ）％～約１００ｗｔ％の塩化第二鉄および約０ｗｔ％～約５０ｗｔ％の塩化第一鉄を含む、［１］に記載のナノ粒子組成物。
［３］ 約０．６５ｇの塩化第二鉄および約０．４ｇの塩化第一鉄を含む、［２］に記載のナノ粒子組成物。
［４］ 前記１つ以上のアミノ基の数が約５～約１５０の範囲である、［１］～［３］のいずれかに記載のナノ粒子組成物。
［５］ 約５０ｗｔ％～約１００ｗｔ％の塩化第二鉄を含む、［１］に記載のナノ粒子組成物。
［６］ 約１．２ｇの塩化第二鉄を含む、［５］に記載のナノ粒子組成物。
［７］ 塩化第一鉄を含まない、［１］、［５］または［６］に記載のナノ粒子組成物。
［８］ 前記１つ以上のアミノ基の数が約２４６～約５００の範囲である、［１］、［５］、［６］または［７］に記載のナノ粒子組成物。
［９］ 塩化第二鉄、塩化第一鉄、またはそれらの組合せと、
デキストランコーティングと
を含む磁性ナノ粒子を含み、
前記磁性ナノ粒子が約６～約４０の範囲の非線形性指数を有する、
ナノ粒子組成物。
［１０］ 約５０重量（ｗｔ）％～約８０ｗｔ％の塩化第二鉄および約５０ｗｔ％～約２０ｗｔ％の塩化第一鉄を含む、［９］に記載のナノ粒子組成物。
［１１］ 約０．５４ｇの塩化第二鉄および約０．２ｇの塩化第一鉄を含む、［１０］に記載のナノ粒子組成物。
［１２］ 前記磁性ナノ粒子が８～１４の範囲の非線形性指数を有する、［１１］に記載のナノ粒子組成物。
［１３］ 約０重量（ｗｔ）％～約５０ｗｔ％の塩化第二鉄および約１００ｗｔ％～約５０ｗｔ％の塩化第一鉄を含むか、または約８０ｗｔ％～約１００ｗｔ％の塩化第二鉄および約０ｗｔ％～約２０ｗｔ％の塩化第一鉄を含む、［９］に記載のナノ粒子組成物。
［１４］ 約０．５４ｇの塩化第二鉄および約０．４ｇの塩化第一鉄を含む、［１３］に記載のナノ粒子組成物。
［１５］ 前記磁性ナノ粒子が約８～約６７の範囲の非線形性指数を有する、［９］または［１３］に記載のナノ粒子組成物。
［１６］ 前記磁性ナノ粒子が約６７の非線形性指数を有する、［１５］に記載のナノ粒子組成物。
［１７］ 前記磁性ナノ粒子が約３ｎｍ～約５０ｎｍの直径を有する酸化鉄結晶コアを有し、前記磁性ナノ粒子の流体力学的直径が約７ｎｍ～約２００ｎｍである、［１］から［１６］のいずれかに記載のナノ粒子組成物。
［１８］ 前記磁性ナノ粒子が約０．１～約０．２５の多分散性を有する、［１］から［１７］のいずれかに記載のナノ粒子組成物。
［１９］ 前記デキストランコーティングが約１ｋＤａ～約１５ｋＤａの範囲の分子量を有するデキストランを含む、［１］から［１８］のいずれかに記載のナノ粒子組成物。
［２０］ 前記デキストランコーティングが約１０ｋＤａの分子量を有するデキストランを含む、［１］から［１９］のいずれかに記載のナノ粒子組成物。
［２１］ 前記デキストランコーティングの表面に付着した薬物ペイロードをさらに含む、［１］から［２０］のいずれかに記載のナノ粒子組成物。
［２２］ 前記薬物ペイロードが前記１つ以上のアミン基とコンジュゲートしたオリゴヌクレオチドである、［１］から［２１］のいずれかに記載のナノ粒子組成物。
［２３］ 前記薬物ペイロードが薬物、抗体、成長因子、核酸、核酸誘導体、核酸断片、タンパク質、タンパク質誘導体、タンパク質断片、糖、多糖断片、糖誘導体、グリコシド、グリコシド断片、グリコシド誘導体、撮像造影剤、またはそれらの任意の組合せである、［１］から［２２］のいずれかに記載のナノ粒子組成物。
［２４］ ［１］から［２３］のいずれかに記載のナノ粒子組成物と、少なくとも１つの薬学的に許容される担体または希釈剤とを含む医薬組成物。
［２５］ 治療有効量の［１］から［２４］のいずれかに記載のナノ粒子組成物を、少なくとも、対象の身体、身体部分、組織、細胞または体液の一部における組織標的部位に投与することと；
エネルギーを前記磁性ナノ粒子組成物および前記組織標的部位に加えることと；
前記ナノ粒子組成物および前記組織標的部位のシグナルを検出することと；
前記検出されたシグナルに基づいて前記組織標的部位の画像を得ることと
を含む、それを必要とする対象における組織標的部位を撮像する方法。
［２６］ 前記撮像が磁気共鳴撮像、磁性粒子撮像、またはそれらの組合せであり、前記エネルギーが磁場である、［２５］に記載の方法。
［２７］ 疾患ががんであり、前記組織標的部位が腫瘍である、［２５］に記載の方法。
［２８］ 前記ナノ粒子組成物が前記対象の前記標的部位に蓄積する、［２５］に記載の方法。
［２９］ それを必要とする対象における疾患を撮像する方法において使用するための、［１］から［２４］のいずれかに記載の組成物。
［３０］ デキストランを水に溶解させることと；
前記デキストランをエピクロロヒドリンで架橋することと；
塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを調製することと；
前記塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを前記デキストランに加えて、混合物を調製することと；
前記混合物を撹拌および氷浴に供しながら、前記混合物に塩基を加えることと；
前記混合物を約７５℃～約９０℃の温度に供することと
を含み、
前記塩基を加えるステップが、酸化鉄結晶、酸化鉄水和物、またはそれらの組合せの形成を妨げ、
前記混合物が、約５０重量（ｗｔ）％～１００ｗｔ％の塩化第二鉄および約０ｗｔ％～５０ｗｔ％の塩化第一鉄を含む、
［１］から［２４］のいずれかに記載のナノ粒子組成物を調製する方法。
［３１］ デキストランを水に溶解させることと；
前記デキストランをエピクロロヒドリンで架橋することと；
塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを調製することと；
前記塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを前記デキストランに加えて、混合物を調製することと；
前記混合物を撹拌および氷浴に供しながら前記混合物に塩基を加えることと；
前記混合物を約７５℃～約９０℃の温度に供することと
を含み、
前記塩基を加えるステップが、酸化鉄結晶、酸化鉄水和物、またはそれらの組合せの形成を妨げ、
前記混合物が、５０ｗｔ％～約８０ｗｔ％の塩化第二鉄および約５０ｗｔ％～約２０ｗｔ％の塩化第一鉄を含む、
［１］から［２４］のいずれかに記載のナノ粒子組成物を調製する方法。
Other Embodiments While the invention has been described in conjunction with a detailed description thereof, the foregoing description is intended to be illustrative and not limiting, the scope of the invention as defined by the appended claims. Please understand that this is not intended. Other aspects, advantages, and modifications are within the scope of the following claims.
Below, the invention described in the original claims of the present application will be added.
[1] Ferric chloride, ferrous chloride, or a combination thereof;
a dextran coating functionalized with one or more amine groups;
containing magnetic nanoparticles containing;
A nanoparticle composition wherein the number of said one or more amine groups ranges from about 5 to about 1000.
[2] The nanoparticle composition according to [1], comprising about 50 wt% to about 100 wt% ferric chloride and about 0 wt% to about 50 wt% ferrous chloride.
[3] The nanoparticle composition according to [2], comprising about 0.65 g of ferric chloride and about 0.4 g of ferrous chloride.
[4] The nanoparticle composition according to any one of [1] to [3], wherein the number of the one or more amino groups ranges from about 5 to about 150.
[5] The nanoparticle composition according to [1], comprising about 50 wt% to about 100 wt% ferric chloride.
[6] The nanoparticle composition according to [5], comprising about 1.2 g of ferric chloride.
[7] The nanoparticle composition according to [1], [5] or [6], which does not contain ferrous chloride.
[8] The nanoparticle composition according to [1], [5], [6] or [7], wherein the number of the one or more amino groups is in the range of about 246 to about 500.
[9] Ferric chloride, ferrous chloride, or a combination thereof;
Dextran coating and
containing magnetic nanoparticles containing;
the magnetic nanoparticles have a nonlinearity index ranging from about 6 to about 40;
Nanoparticle composition.
[10] The nanoparticle composition of [9], comprising about 50 wt% to about 80 wt% ferric chloride and about 50 wt% to about 20 wt% ferrous chloride.
[11] The nanoparticle composition according to [10], comprising about 0.54 g of ferric chloride and about 0.2 g of ferrous chloride.
[12] The nanoparticle composition according to [11], wherein the magnetic nanoparticles have a nonlinearity index in the range of 8 to 14.
[13] comprising about 0 weight (wt)% to about 50 wt% ferric chloride and about 100 wt% to about 50 wt% ferrous chloride, or about 80 wt% to about 100 wt% ferric chloride and The nanoparticle composition according to [9], comprising about 0 wt% to about 20 wt% ferrous chloride.
[14] The nanoparticle composition according to [13], comprising about 0.54 g of ferric chloride and about 0.4 g of ferrous chloride.
[15] The nanoparticle composition according to [9] or [13], wherein the magnetic nanoparticles have a nonlinearity index in the range of about 8 to about 67.
[16] The nanoparticle composition according to [15], wherein the magnetic nanoparticles have a nonlinearity index of about 67.
[17] [1] to [16], wherein the magnetic nanoparticles have an iron oxide crystalline core having a diameter of about 3 nm to about 50 nm, and the hydrodynamic diameter of the magnetic nanoparticles is about 7 nm to about 200 nm. The nanoparticle composition according to any one of .
[18] The nanoparticle composition according to any one of [1] to [17], wherein the magnetic nanoparticles have a polydispersity of about 0.1 to about 0.25.
[19] The nanoparticle composition according to any one of [1] to [18], wherein the dextran coating comprises dextran having a molecular weight in the range of about 1 kDa to about 15 kDa.
[20] The nanoparticle composition according to any one of [1] to [19], wherein the dextran coating comprises dextran having a molecular weight of about 10 kDa.
[21] The nanoparticle composition according to any one of [1] to [20], further comprising a drug payload attached to the surface of the dextran coating.
[22] The nanoparticle composition according to any one of [1] to [21], wherein the drug payload is an oligonucleotide conjugated with the one or more amine groups.
[23] The drug payload is a drug, antibody, growth factor, nucleic acid, nucleic acid derivative, nucleic acid fragment, protein, protein derivative, protein fragment, sugar, polysaccharide fragment, sugar derivative, glycoside, glycoside fragment, glycoside derivative, imaging contrast agent, or any combination thereof, the nanoparticle composition according to any one of [1] to [22].
[24] A pharmaceutical composition comprising the nanoparticle composition according to any one of [1] to [23] and at least one pharmaceutically acceptable carrier or diluent.
[25] A therapeutically effective amount of the nanoparticle composition according to any one of [1] to [24] is administered to a tissue target site in at least a portion of the body, body part, tissue, cell, or body fluid of a subject. Koto;
applying energy to the magnetic nanoparticle composition and the tissue target site;
detecting a signal of the nanoparticle composition and the tissue target site;
obtaining an image of the tissue target site based on the detected signal;
A method of imaging a tissue target site in a subject in need thereof, including:
[26] The method according to [25], wherein the imaging is magnetic resonance imaging, magnetic particle imaging, or a combination thereof, and the energy is a magnetic field.
[27] The method according to [25], wherein the disease is cancer and the tissue target site is a tumor.
[28] The method according to [25], wherein the nanoparticle composition accumulates at the target site of the subject.
[29] The composition according to any one of [1] to [24] for use in a method of imaging a disease in a subject in need thereof.
[30] Dissolving dextran in water;
crosslinking the dextran with epichlorohydrin;
preparing a ferrous chloride solution, a ferric chloride solution, or a combination thereof;
adding the ferrous chloride solution, ferric chloride solution, or a combination thereof to the dextran to prepare a mixture;
adding a base to the mixture while stirring and subjecting the mixture to an ice bath;
subjecting the mixture to a temperature of about 75°C to about 90°C;
including;
the step of adding a base prevents the formation of iron oxide crystals, iron oxide hydrates, or combinations thereof;
the mixture comprises about 50 wt% to 100 wt% ferric chloride and about 0 wt% to 50 wt% ferrous chloride;
A method for preparing the nanoparticle composition according to any one of [1] to [24].
[31] Dissolving dextran in water;
crosslinking the dextran with epichlorohydrin;
preparing a ferrous chloride solution, a ferric chloride solution, or a combination thereof;
adding the ferrous chloride solution, ferric chloride solution, or a combination thereof to the dextran to prepare a mixture;
adding a base to the mixture while stirring and subjecting the mixture to an ice bath;
subjecting the mixture to a temperature of about 75°C to about 90°C;
including;
the step of adding a base prevents the formation of iron oxide crystals, iron oxide hydrates, or combinations thereof;
the mixture comprises 50 wt% to about 80 wt% ferric chloride and about 50 wt% to about 20 wt% ferrous chloride;
A method for preparing the nanoparticle composition according to any one of [1] to [24].
Claims (31)
１つ以上のアミン基で官能化されたデキストランコーティングと
を含む磁性ナノ粒子を含み、
前記１つ以上のアミン基の数が約５～約１０００の範囲である、ナノ粒子組成物。 ferric chloride, ferrous chloride, or a combination thereof;
a dextran coating functionalized with one or more amine groups;
A nanoparticle composition wherein the number of said one or more amine groups ranges from about 5 to about 1000.
デキストランコーティングと
を含む磁性ナノ粒子を含み、
前記磁性ナノ粒子が約６～約４０の範囲の非線形性指数を有する、
ナノ粒子組成物。 ferric chloride, ferrous chloride, or a combination thereof;
dextran coating and magnetic nanoparticles,
the magnetic nanoparticles have a nonlinearity index ranging from about 6 to about 40;
Nanoparticle composition.
エネルギーを前記磁性ナノ粒子組成物および前記組織標的部位に加えることと；
前記ナノ粒子組成物および前記組織標的部位のシグナルを検出することと；
前記検出されたシグナルに基づいて前記組織標的部位の画像を得ることと
を含む、方法。 25. A method of imaging a tissue target site in a subject, wherein a therapeutically effective amount of a nanoparticle composition according to any one of claims 1 to 24 is applied to at least a body, body part, tissue, cell or body fluid of a subject. has been previously administered to a tissue target site in a portion of the
applying energy to the magnetic nanoparticle composition and the tissue target site;
detecting a signal of the nanoparticle composition and the tissue target site;
obtaining an image of the tissue target site based on the detected signal.
前記デキストランをエピクロロヒドリンで架橋することと；
塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを調製することと；
前記塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを前記デキストランに加えて、混合物を調製することと；
前記混合物を撹拌および氷浴に供しながら、前記混合物に塩基を加えることと；
前記混合物を約７５℃～約９０℃の温度に供することと
を含み、
前記塩基を加えるステップが、酸化鉄結晶、酸化鉄水和物、またはそれらの組合せの形成を妨げ、
前記混合物が、約５０重量（ｗｔ）％～１００ｗｔ％の塩化第二鉄および約０ｗｔ％～５０ｗｔ％の塩化第一鉄を含む、
請求項１から２４のいずれか一項に記載のナノ粒子組成物を調製する方法。 dissolving dextran in water;
crosslinking the dextran with epichlorohydrin;
preparing a ferrous chloride solution, a ferric chloride solution, or a combination thereof;
adding the ferrous chloride solution, ferric chloride solution, or a combination thereof to the dextran to prepare a mixture;
adding a base to the mixture while stirring and subjecting the mixture to an ice bath;
subjecting the mixture to a temperature of about 75°C to about 90°C;
the step of adding a base prevents the formation of iron oxide crystals, iron oxide hydrates, or combinations thereof;
the mixture comprises about 50 wt% to 100 wt% ferric chloride and about 0 wt% to 50 wt% ferrous chloride;
25. A method of preparing a nanoparticle composition according to any one of claims 1 to 24.
前記デキストランをエピクロロヒドリンで架橋することと；
塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを調製することと；
前記塩化第一鉄溶液、塩化第二鉄溶液、またはそれらの組合せを前記デキストランに加えて、混合物を調製することと；
前記混合物を撹拌および氷浴に供しながら前記混合物に塩基を加えることと；
前記混合物を約７５℃～約９０℃の温度に供することと
を含み、
前記塩基を加えるステップが、酸化鉄結晶、酸化鉄水和物、またはそれらの組合せの形成を妨げ、
前記混合物が、５０ｗｔ％～約８０ｗｔ％の塩化第二鉄および約５０ｗｔ％～約２０ｗｔ％の塩化第一鉄を含む、
請求項１から２４のいずれか一項に記載のナノ粒子組成物を調製する方法。
dissolving dextran in water;
crosslinking the dextran with epichlorohydrin;
preparing a ferrous chloride solution, a ferric chloride solution, or a combination thereof;
adding the ferrous chloride solution, ferric chloride solution, or a combination thereof to the dextran to prepare a mixture;
adding a base to the mixture while stirring and subjecting the mixture to an ice bath;
subjecting the mixture to a temperature of about 75°C to about 90°C;
the step of adding a base prevents the formation of iron oxide crystals, iron oxide hydrates, or combinations thereof;
the mixture comprises 50 wt% to about 80 wt% ferric chloride and about 50 wt% to about 20 wt% ferrous chloride;
25. A method of preparing a nanoparticle composition according to any one of claims 1 to 24.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943927P | 2019-12-05 | 2019-12-05 | |
| US62/943,927 | 2019-12-05 | ||
| PCT/US2020/063635 WO2021113829A1 (en) | 2019-12-05 | 2020-12-07 | Compositions and methods for tunable magnetic nanoparticles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023504525A JP2023504525A (en) | 2023-02-03 |
| JPWO2021113829A5 true JPWO2021113829A5 (en) | 2023-12-13 |
Family
ID=76222708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533152A Pending JP2023504525A (en) | 2019-12-05 | 2020-12-07 | Compositions and methods for tunable magnetic nanoparticles |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230020016A1 (en) |
| EP (1) | EP4069317A4 (en) |
| JP (1) | JP2023504525A (en) |
| KR (1) | KR20220110532A (en) |
| CN (1) | CN115066265A (en) |
| AU (1) | AU2020397185A1 (en) |
| CA (1) | CA3163946A1 (en) |
| WO (1) | WO2021113829A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023235299A1 (en) * | 2022-05-31 | 2023-12-07 | The Board Of Trustees Of The University Of Illinois | Fluorophore-loaded gelatin-based nanoparticles for near-infrared imaging |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2685464T3 (en) * | 2008-04-04 | 2018-10-09 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and methods of use thereof |
| CN102430130B (en) * | 2011-11-24 | 2012-12-12 | 北京化工大学 | Medical modified glucan coated magnetic nanometer particle composite material and preparation method thereof |
| CN102631687A (en) * | 2012-05-07 | 2012-08-15 | 西安电子科技大学 | Multifunctional magnetic nano-carrier for targeted delivery of microRNA, preparation method and application thereof |
| CN106913885B (en) * | 2015-12-28 | 2020-05-08 | 中国科学院宁波材料技术与工程研究所 | Magnetic nano particle and preparation method and application thereof |
| CN106568936B (en) * | 2016-10-12 | 2018-04-24 | 宁波大学 | The preparation method and applications of miRNA-21 electrochemical luminescence immunosensors based on multifunction molybdenum disulfide |
| WO2018098705A1 (en) * | 2016-11-30 | 2018-06-07 | 硕英生医股份有限公司 | Dextran-magnetic iron oxide nanoparticle, preparation and use in treating cancer and as contrast |
| CN107670036B (en) * | 2017-09-30 | 2020-12-08 | 中国科学院长春应用化学研究所 | Dissociation method of iron coordination polymer nanoparticles and application thereof |
-
2020
- 2020-12-07 EP EP20895792.8A patent/EP4069317A4/en active Pending
- 2020-12-07 CN CN202080095773.6A patent/CN115066265A/en active Pending
- 2020-12-07 AU AU2020397185A patent/AU2020397185A1/en active Pending
- 2020-12-07 US US17/782,369 patent/US20230020016A1/en active Pending
- 2020-12-07 WO PCT/US2020/063635 patent/WO2021113829A1/en unknown
- 2020-12-07 KR KR1020227022437A patent/KR20220110532A/en unknown
- 2020-12-07 CA CA3163946A patent/CA3163946A1/en active Pending
- 2020-12-07 JP JP2022533152A patent/JP2023504525A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6767635B1 (en) | Magnetic nanoparticles having biochemical activity, method for the production thereof and their use | |
| Lim et al. | Hyaluronan-modified magnetic nanoclusters for detection of CD44-overexpressing breast cancer by MR imaging | |
| RU2500622C2 (en) | Magnetic converters review | |
| JP2012528197A (en) | Nanodiamond particle composite | |
| KR101725240B1 (en) | DUAL STIMULI-RESPONSIVE CORE-SHELL MAGNETIC NANOPARTICLE HAVING UV-LIGHT RESPONSIVITY AND pH-RESPONSIVITY, AND DRUG DELIVERY COMPISING THE SAME | |
| US20100040694A1 (en) | Low-molecular weight, water-soluble chitosan nanoparticle for gene delivery with folic acid conjugaed thereto as target ligand and preparation method thereof | |
| TWI572369B (en) | Development of ph-responsive nanoparticles and use of ph-responsive nanoparticles for preparing enhanced tumor permeation and uptake of anticancer drugs | |
| JP2021181441A (en) | Dually derivatized chitosan nanoparticles, and methods of making, and using the same for gene transfer in vivo | |
| CN113372412B (en) | Cell-targeted polypeptide for treating bone tumor and preparation method and application thereof | |
| US20230310624A1 (en) | Affibody-cytotoxin conjugate for active targeted therapy of tumors, nanoparticle thereof, preparation method thereof and application thereof | |
| CN111601622A (en) | Preparation method of preparation based on iron oxide magnetic nanoparticles for magnetic resonance imaging diagnosis of tumors | |
| JP5185532B2 (en) | Ferrofluid using stable ferrofluid in neutral medium and particles with modified surface | |
| US20200030238A1 (en) | Microspheres containing therapeutic agents and related methods of use | |
| JP2009531302A (en) | Targeted iron oxide nanoparticles | |
| Tarhan et al. | Synthesis and characterization of new branched magnetic nanocomposite for loading and release of topotecan anti-cancer drug | |
| JP2009114066A (en) | Organic magnetic nanocomplex having functional molecule introduced therein | |
| KR101586866B1 (en) | pH sensitive nano particle for drug delivery and preparation method thereof | |
| Khoshnood et al. | N doped-carbon quantum dots with ultra-high quantum yield photoluminescent property conjugated with folic acid for targeted drug delivery and bioimaging applications | |
| JPWO2021113829A5 (en) | ||
| CN115120738B (en) | Imiquimod prodrug nano-particles, and preparation method and application thereof | |
| US20190133949A1 (en) | Microspheres containing therapeutic agents and related methods of use | |
| CN114159560A (en) | Preparation method and application of GSH (glutathione-phosphate) and PH dual-response chemotherapy and photothermal combined treatment drug delivery carrier | |
| WO2022125031A1 (en) | Trimethyl chitosan nanoparticles containing magnetic- targeted gemcitabine | |
| CN106214639B (en) | A kind of preparation method of chitosan scion grafting cetirizine nano-micelle | |
| JP2007220867A (en) | Water-dispersible magnetic nanoparticle |